Back to top

Image: Bigstock

Biotechnology ETF (IBB) Hits New 52-Week High

Read MoreHide Full Article

For investors seeking momentum, iShares Nasdaq Biotechnology ETF (IBB - Free Report)  is probably on radar. The fund just hit a 52-week high and is up about 34.3% from its 52-week low price of $89.01/share.

But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:

IBB in Focus

This fund seeks to provide exposure to U.S. biotechnology stocks and tracks the NASDAQ Biotechnology Index. It comprises about 215 holdings. It charges a fee of 47 basis points a year.

Why the Move?

FDA approvals, solid merger-acquisition environment and positive drug data have been driving the sector and the related funds like IBB ahead.

More Gains Ahead?

Currently, the fund has a positive weighted alpha of 15.80. So, there is definitely some promise for those who want to ride on this ETF a little longer.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


ISHARES NDQ BIO (IBB) - free report >>

Published in